PRI 200
Alternative Names: PRI-200Latest Information Update: 10 Oct 2022
At a glance
- Originator Priavoid
- Class Antidementias; Peptides
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Tauopathies
Most Recent Events
- 22 Sep 2022 PRI 200 is available for licensing as of 22 Sep 2022. https://priavoid.com/partnering-and-investors/
- 13 Sep 2022 Preclinical trials in Alzheimer's disease in Germany (unspecified route) (Priavoid pipeline, September 2022)
- 13 Sep 2022 Preclinical trials in Neurodegenerative disorders in Germany (unspecified route) Before September 2022